Nvidia signs deal with Genentech to pair drugmaker's machine learning with chip supplier's tech
Roche’s Genentech unit and Nvidia, the supercomputing hardware powerhouse, have signed a multi-year deal to speed up the pharma’s R&D work by using artificial intelligence, the companies said Tuesday.
The partnership is the latest step in Genentech’s growing AI ambitions, led by Aviv Regev, the biotech’s head of research and early development. Genentech established a computational sciences team earlier this year that has grown to about 400 full-time employees. That group includes Prescient Design, an AI biotech startup based in New York that Genentech bought in 2021.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.